Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (1266)	11/14/2002 4:48:15 AM
From: nigel bates	Read Replies (1) \| Respond to of 1784

Evotec Technologies EVOscreen Mark III successfully passed site acceptance testing at Novartis Hamburg, Germany - Evotec Technologies GmbH, a subsidiary of Evotec OAI AG (Xetra: 566480.DE - news) (Neuer Markt (Xetra: news) : EVT) providing innovative technologies for life sciences, announced today the implementation of the second ultra-high-throughput screening (uHTS) system to its long-term partner Novartis ( NOVZn.VX - news) , Basle, Switzerland. In addition to EVOscreenÂ® Mark II the next generation Mark III now successfully passed site acceptance (SAT) procedures ahead of time. During a period of three weeks several functional, robustness and precision tests were performed including the screening of biochemical and cellular assays as well as 24 hour runs. "The results achieved in terms of robustness, precision and data quality were excellent and significantly exceeded the agreed pass criteria", said Dr Johannes Ottl, Labhead Nanoscreening at Novartis Pharma AG. "We are very proud of the excellent results achieved in a remarkable team effort. I want to thank all employees involved at Evotec and Novartis for their continued support," said Dr Timm Jessen, Chief Scientific Officer of Evotec OAI. "We once again demonstrated our ability to successfully deliver cutting edge technology systems with the help of our experience in drug discovery technologies in close collaboration with our long-term partner Novartis." "We are very satisfied by the technological specifications of the Mark III screening system and the close and productive collaboration between the teams at Novartis and Evotec," said Dr Lorenz Mayr, Technology Program Head, Assay Development and Nanoscreening at Novartis Pharma AG. The EVOscreenÂ® Mark III system has been built on the success of the EVOscreenÂ® Mark II design. Mark III, however, now integrates a series of important technological advances. Evotec Technologies' proprietary single molecule reader as well as parallel dispensing of micropumps enable the throughput of above 100,000 tests per day in homogenous as well as cellular assay systems. In addition, the open system architecture simplifies the use of external components giving Evotec Technologies the flexibility to stay on the cutting edge of screening technology combining its own developments with standard external solutions.